COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Shares of Compass Pathways Plc continue to trade within highly speculative territory, closing the week at $5.23 with a marginal gain of $0.01. Beneath this surface-level stability lies a fundamental ...

Investing.com - Oppenheimer has upgraded Compass Pathways (NASDAQ:CMPS) from Perform to Outperform, setting a price target of $15.00 based on the potential of its psilocybin therapy for ...

With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Compass Pathways Plc is conducting a ...

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help ...

Oppenheimer upgraded Compass Pathways (CMPS) to Outperform from Perform with a $15 price target The firm is citing it higher conviction that the company’s COMP360 will “lead the revolution of ...

COMPASS Pathways PLC ADR stock grades by Barron's. View CMPS fundamental and sentiment analysis powered by MarketGrader.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in ...

(RTTNews) - Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements ...